Virtual Screening TLR2 Antagonists for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for discovering small molecule TLR2 antagonists are inefficient and lack effective pharmacological targets for preventing or treating inflammatory diseases, with a need for novel compounds that can inhibit TLR2 signaling without causing toxicity.
Innovation Solution
Development of 19 novel small molecule TLR2 antagonists with high oral bioavailability, characterized by their ability to inhibit IL-8 secretion and function as regulators of TLR4, utilizing a combination of virtual screening techniques, pharmacophore modeling, and molecular docking to identify compounds like S06690562, S01688300, and S01382085 for use in pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If experimental high-throughput screening (HTS) is used to discover TLR2 antagonists, then the reliability of identifying active compounds is improved, but the cost and time consumption increase significantly
Solution Approach 1:
The patent applies preliminary action by performing virtual screening of compound libraries against TLR2 receptor models before conducting experimental validation. This pre-screening step filters out inactive compounds computationally, allowing only the most promising candidates to proceed to expensive and time-consuming wet lab experiments, thereby reducing overall screening time while maintaining reliability
Solution Approach 2:
The patent introduces computational modeling and virtual screening as an intermediary between compound library storage and experimental testing. This intermediary layer uses in silico methods to predict binding affinity and activity, serving as a bridge that reduces the number of compounds requiring experimental validation while preserving the ability to identify true active compounds
2Productivity
If the compound library is reduced to a small set for screening, then the screening cost and time are reduced, but the risk of missing specific target drugs increases
Solution Approach 1:
The patent applies parameter changes by optimizing multiple computational parameters simultaneously: filtering criteria for compound selection, docking scoring functions, and virtual screening thresholds. By carefully tuning these parameters, the method identifies a small subset of compounds that maintains high probability of containing the specific target drug while reducing screening scope
Solution Approach 2:
The patent creates a multi-functional virtual screening platform that can evaluate compounds against multiple targets and conditions simultaneously. This universal approach allows the small reduced library to be assessed comprehensively using various computational metrics, increasing confidence that the specific target drug is not missed despite the reduced screening scope
3Device complexity
If ligand-based virtual screening is used, then the screening process is simplified, but it requires prior information about active ligands which may not be available
Solution Approach 1:
The patent applies inversion by reversing the traditional screening approach: instead of starting with known active ligands and finding similar compounds (ligand-based), or using complex receptor structures (receptor-based), the method uses simplified pharmacophore models that can be constructed with minimal prior information, making the process both simple and broadly applicable
4Measurement precision
If molecular docking is performed with high-resolution receptor coordinates, then the binding affinity prediction accuracy is improved, but the computational resources and time required increase
Solution Approach 1:
The patent applies partial action by performing molecular docking only on the small subset of compounds that passed virtual screening, rather than docking the entire compound library. This partial application of the computationally intensive docking method maintains high prediction accuracy for the most promising candidates while dramatically reducing overall computational resource requirements
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to a novel small molecule TLR2 antagonist, and particularly, to 19 novel TLR2 antagonists, a pharmaceutical composition, including the antagonists, for preventing or treating inflammatory diseases, and a TLR4 regulator. The novel TLR2 antagonists according to the present disclosure can be effectively used as a preparation for oral administration by having low molecular weight and high oral bioavailability, and can be useful in pharmaceutical compositions for preventing or treating inflammatory diseases since the secretion of IL-8 is effectively inhibited and in vivo cytotoxicity is not induced. In addition, the novel TLR2 antagonists according to the present disclosure can be used as a TLR4 regulator.